Hägglund H, Boström L, Remberger M, Ljungman P, Nilsson B, Ringdén O
Department of Clinical Immunology and Transplantation Surgery, Huddinge Hospital, Sweden.
Bone Marrow Transplant. 1995 Dec;16(6):747-53.
We analysed 35 risk factors for acute GVHD in 291 consecutive recipients of HLA-identical sibling marrow transplants from 1975 to 1993. Of these, 16% developed moderate-to-severe acute GVHD following transplantation. In multivariate analysis, GVHD prophylaxis with monotherapy (MTX or CsA) (P = 0.015) seropositivity for several herpes viruses in the donor (P = 0.015) and seropositivity for CMV in the recipient (P = 0.037) before the transplants as well as early engraftment (P = 0.016), were the principal risk factors for GVHD. A high serum TNF-alpha level during conditioning therapy was also a significant risk factor in 75 recipients (P = 0.005). The risk of grades II-IV acute GVHD increased with the number of risk factors. Thus the cumulative incidence of acute GVHD was 1%, if no risk factor was present, 4% with one, 9% with two, 21% with three and 44% in patients with four risk factors. Factors reported to correlate with acute GVHD, such as age, diagnosis, female donor to male recipient, relative response and donor-responding capacity in MLC, MNS blood group antigen, splenectomy and bone marrow cell dose were not associated with acute GVHD in this study. Five-year survival was 24% in patients with grades II-IV GVHD vs 62% in patients with grades 0-I GVHD (P = 0.0001).
我们分析了1975年至1993年间连续291例接受 HLA 相同的同胞骨髓移植受者的35个急性移植物抗宿主病(GVHD)风险因素。其中,16%的患者在移植后发生了中度至重度急性GVHD。多因素分析显示,单药预防GVHD(甲氨蝶呤或环孢素A)(P = 0.015)、供者多种疱疹病毒血清学阳性(P = 0.015)、移植前受者巨细胞病毒血清学阳性(P = 0.037)以及早期植入(P = 0.016)是GVHD的主要风险因素。在75例受者中,预处理治疗期间高血清肿瘤坏死因子-α水平也是一个显著的风险因素(P = 0.005)。II-IV级急性GVHD的风险随风险因素数量的增加而增加。因此,如果不存在风险因素,急性GVHD的累积发生率为1%,有一个风险因素时为4%,有两个风险因素时为9%,有三个风险因素时为21%,有四个风险因素时为44%。在本研究中,既往报道的与急性GVHD相关的因素,如年龄、诊断、女性供者对男性受者、混合淋巴细胞培养中的相对反应和供者反应能力、MNS血型抗原、脾切除术和骨髓细胞剂量,均与急性GVHD无关。II-IV级GVHD患者的5年生存率为24%,而0-I级GVHD患者为62%(P = 0.0001)。